Less than a week after a federal appeals court heard arguments in New York state’s challenge of an Actavis plc plan to switch Alzheimer’s patients to a new version of the drug Namenda, a Philadelphia district judge on Thursday rejected similar “product-hopping” allegations, clearing Warner Chilcott plc of antitrust liability in a separate case.

Warner Chilcott is represented by J. Mark Gidley and Peter Carney of White & Case, along with Ballard Spahr’s Edward Rogers.

Related Practices

Health Care
Intellectual Property